Compare BridgeBio Pharma Inc (BBIO) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ProShares Ultra Semiconductors — how do they compare? BridgeBio Pharma Inc trades at $83.1 (market cap $16.46B), while ProShares Ultra Semiconductors trades at $93.99. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| BBIO | USD | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $113.53 |
52-Week Low | $44.81 | $39.58 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
USD stock trades at $89.20, down 8.0% over 24 hours amid broader market volatility. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The company announced a future dividend of $0.14 per share scheduled for June 30, 2026. Recent news highlights include coverage of semiconductor sector performance and earnings reports from various firms, though specific financials for USD are not detailed in available data.
The outlook hinges on execution of business strategy and market conditions. Opportunities include potential dividend returns and sector tailwinds, but risks involve price volatility and competitive pressures. Investors should monitor upcoming financial disclosures for fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
